Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences has launched its ColoSTAT Access Program in Australia, enrolling the first physician participant and formally moving the blood-based colorectal cancer test from clinical development into structured commercial deployment. The program provides an initial no-cost allocation of tests to up to 20 clinicians to establish safe, routine ordering and usage processes before transitioning them to standard commercial pricing.
Through this controlled rollout, Rhythm aims to demonstrate ColoSTAT’s operational readiness, generate real-world performance and utilisation data, and refine workflows for broader market deployment. The initiative seeks to validate clinician demand for a less invasive blood test alternative to existing colorectal cancer screening methods, potentially improving screening participation and supporting future reimbursement and partner engagement.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is a predictive cancer diagnostics technology company focused on developing and commercialising blood-based tests, with a key product being ColoSTAT for colorectal cancer screening. The company is targeting routine clinical use and revenue-generating deployment in Australia as it builds pathways for broader market access and clinician adoption.
Average Trading Volume: 819,903
Technical Sentiment Signal: Buy
Current Market Cap: A$82.63M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.